RESULTS: Of the 186 participants, 99% ever reported using the diaphragm, and, at study exit, 96% had used it in the previous 2 months. Consistent diaphragm use since the previous visit was reported by 13% to 16% of the women, and in multivariate regression analysis, it was significantly associated with never using condoms (adjusted odds ratio, 24.08; 95% confidence interval, 6.71-86.34). Other factors included discreet use, preferring diaphragms to condoms, timing of insertion, domestic violence, and contraception. CONCLUSION: Diaphragms were well accepted among women at risk for sexually transmitted diseases/HIV. 
Critical Issues in Contraceptive and STI Acceptability Research

PUBLISHED ABSTRACT
We review conceptual issues and theoretical frameworks related to users' acceptability of new technologies designed to protect reproductive health and prevent unwanted pregnancy. Special attention is given to distinctions among different kinds of users' perspectives regarding acceptability, as well as differentiating acceptability from assessments of the efficacy of innovative methods. Emphasis is also given to the larger context of couple decision-making and cultural variation. We argue that concern for sexual pleasure plays a central role in determining user perspectives regarding new methods. The female condom, contraceptive ring, contraceptive skin patch, microbicides, vaccines, emergency contraception, and PERSONA are discussed within the context of the identified critical issues. , Ltd. U.K., the manufacturer of the Prentif™ Cervical Cap, will no longer carry product liability insurance and has substantially increased prices due to declining sales. In addition, they report that the U.K. manufacturing plant for the Prentif™ Cervical Cap will close in a few months. Beyond this statement, there is no additional information available from Cervical Cap, Ltd. about whether or not the Prentif™ Cervical Cap will continue to be available outside of the U.S.
Supply
The cervical cap has been used in Europe since the mid 1800's and in the U.S. since the 1920's. The Prentif™ Cervical Cap was approved by the Food and Drug Administration in 1988.
The Cervical Barrier Advancement Society (CBAS) is disappointed by the recent news that the Prentif™ Cervical Cap will no longer be available in the U.S. Cervical Cap, Ltd., which closed its doors in March 2005, was the sole distributor of the Prentif™ Cervical Cap in the U.S.
With the company's closure, American women lose access to a safe, effective contraceptive option. While cervical cap use has been declining in the U.S., this method remains an important option for many women, including those who need or want a nonhormonal contraceptive method.
We hope that women who currently use the Prentif™ Cervical Cap will be able to access information on other cervical barrier options (the CBAS website, www.cervicalbarriers.org, provides detailed information on cervical barriers), and hope to see new products come on the market in the future.
New Report on Female Condom
The UNAIDS Global Coalition on Women and AIDS (GCWA) and the Global Campaign for Microbicides (GCM) sponsored an experts' consultation in December 2004 to examine barriers and opportunities for increasing access to the female condom.
The meeting sought input from a number of individuals with experience researching, programming, advocating for and/or funding female condom programs.
The main recommendations of the report are to re-orient the public health paradigm of providing people with a range of options, tailoring messages to specific audiences, and helping people reduce their HIV/STI risk, by:
• Positioning female condom as an integral (not optional) part of HIV prevention, care and treatment strategies--both existing and future.
• Integrating female condom provision specifically into the expansion of voluntary counseling and testing (VCT) programs, accompanying the roll out of antiretroviral therapy (ART) programs, as part of risk reduction counseling for serodiscordant couples, and into mother to child transmission (MTCT) programs that identify HIV positive and negative women through perinatal testing.
• Evaluating the pros and cons of actively promoting re-use of the female condom as a risk-reduction strategy.
A short report from the meeting is available here ( w w w . g l o b a l -c a m p a i g n . o r g / c l i e n t f i l e s /
Reproductive Health Technologies Project Updates Site
The Reproductive Health Technologies Project (RHTP), a member of CBAS, has launched an u p d a t ed v e r s i on o f t h e i r w e b s i t e : www.rhtp.org. The new site contains information on cervical barriers and many other reproductive health products and issues.
RHTP is a Washington, DC-based non-profit organization working to advance the ability of every woman to achieve full reproductive freedom with access to the safest, most effective, and preferred methods for controlling her fertility and protecting her health.
Prentif™ Cervical Cap display
U.S. Government Report on
Nonoxynol-9
The United States General Accountability Office (GAO) recently released a report entitled "Efforts to research and inform the public about Nonoxynol-9 and HIV." The GAO is the audit, evaluation and investigative arm of Congress and issues reports periodically to help improve the performance and accountability of the federal government for the American people.
This report, prepared at the request of four members of the U.S. Congress (Souder, R-IN; Coburn, R-OK; Pitts, R-PA; and Weldon, R-FL), describes the federal agencies' and product manufacturers' actions to assess the safety and effectiveness of N-9 as a microbicide and the level of information subsequently provided to the public about this topic. The report is posted on the Global Campaign for
M i c r o b i c i d e s w e b s i t e (www.global-campaign.org).
The information released in the GAO report regarding Nonoxynol-9 is fair and accurate, and while there has been some confusion in the past regarding the potential efficacy of N-9 for the prevention of HIV/STIs before it's effects were well-known, the following guidelines are now widely accepted:
• N-9 is a safe, effective contraceptive option for women at low risk for HIV/STIs who do not use the product more than once a day; • N-9 should not be used to prevent HIV/ STIs; and • N-9 should not be used rectally.
The GAO report notes that the U.S. Food and Drug Administration is finalizing its rule to require warning labels on vaginal contraceptives containing N-9 and expects to publish this final rule by September 2005. In addition, the FDA is planning to propose that new warning labels be added to condoms, and will be posting a draft of this proposal for public comment in May 2005. An N-9 Fact Sheet is available in the CBAS download center (www.cervicalbarriers.org).
FDA Re-approves Today Sponge ® for Sale in the U.S. Allendale plans to make the sponge available to U . S .
w o m e n t h r o u g h t h e i r w e b s i t e (www.allendalepharm.com) in June and in U.S. stores by August. The sponges will be sold in packs of three and will be priced between $2.50 and $3.00 per sponge. Allendale, which is planning an advertising campaign for the sponge, says it expects to sell about 15 million sponges in the first year of sales.
Spanish Version of Cervical Barriers Presentation
In cooperation with the Population Council's Latin America and Caribbean office, a Spanish language version of the CBAS general cervical barrier methods presentation has been produced and is now available in the CBAS download center (www.cervicalbarriers.org).
To comment on anything you read in the CBAS newsletter or to contribute a story, event, or news item, please email info@cervicalbarriers.org.
